Acute Lower gastroIntestinal BleedIng (ALIBI Study) in Italy

Acute Lower gastroIntestinal BleedIng (ALIBI Study): a Multicentre Prospective, Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04364412

Acronym

ALIBI

Enrollment

1198

Registered

2020-04-28

Start date

2019-04-01

Completion date

2020-05-18

Last updated

2020-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower GI Bleeding

Brief summary

Unlike upper GI bleeding, for LGIB there is still a paucity of data on clinical presentation, patient characteristics, pathways of care and outcomes for LGIB patients. In-hospital mortality ranges from 1.2% to 8.8% (2-4), according to retrospective studies, but data from prospective series are still limited (5). Present multicentre, prospective, observational study was designed to explore these areas, to assess variations in practice management and to identify factors associated with patient outcomes.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* adult patients with acute lower GI bleeding

Exclusion criteria

* age below 18 years * bleeding patients with an upper GI source

Design outcomes

Primary

Measure	Time frame	Description
Mortality rate in patients admitted for acute lower GI bleeding	4 weeks	Number of deaths among the study cohort

Countries

Italy

Outcome results